---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-018543"
form_type: "8-K"
ticker: null
cik: "0001792581"
company_name: "Kiromic Biopharma, Inc."
filed_at: "2022-12-12T23:59:59+00:00"
generated_at: "2026-06-21T06:16:12.130036+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kiromic BioPharma receives Nasdaq deficiency notice for audit committee non-compliance

## Summary
- Frank Tirelli resigned as director effective Nov 16, 2022, leaving audit committee with fewer than 3 independent members.
- Nasdaq requires audit committee of at least 3 independent directors per Listing Rule 5605(c)(2)(A).
- Cure period until earlier of next annual shareholders' meeting or Nov 16, 2023; stock continues trading on Nasdaq.
- Board's Nominating and Corporate Governance Committee is seeking qualified candidates to fill vacancy.

## SEC filing metadata
- accession: 0001558370-22-018543
- form_type: 8-K
- cik: 0001792581
- company_name: Kiromic Biopharma, Inc.
- filed_at: 2022-12-12T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1792581/000155837022018543/0001558370-22-018543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1792581/000155837022018543/krbp-20221212x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-018543
- JSON: https://secwatch.observer/filing/0001558370-22-018543.json
- Plain text: https://secwatch.observer/filing/0001558370-22-018543.txt

## Key facts
- Listing & Compliance Notices
  Kiromic Biopharma, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: audit committee
  - Rules: 5605(c)(2)(A)
  source text: December 6, 2022, Kiromic BioPharma, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is no longer in compliance with the audit committee requirements as set forth in Nasdaq Listing Rule 5605 for continued listing on The Nasdaq Capital Market. ​ Nasdaq Listing Rule 5605(c)(2)(A) requires companies listed on The Nasdaq Capital Market to maintain an audit committee consisting of at least three independent directorsmembers, with one of which being classified as a financial expert. As
  evidence_url: https://www.sec.gov/Archives/edgar/data/1792581/000155837022018543/0001558370-22-018543-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.